Brean Capital Remains Sidelined on NetApp (NTAP) Following Annual User Conference
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
Summit Redstone Upgrades NetApp (NTAP) to Buy
September 30, 2016 6:31 AM EDTSummit Redstone upgraded NetApp (NASDAQ: NTAP) from Hold to Buy with a price target of $45.00.
Analyst Srini Nandury highlighted:
We are optimistic that the company can grow its product revenue from current levels driven by AFA sales and increasing adoption of clustered ONTAP... MoreSusquehanna Reiterates Positive Rating on NetApp (NTAP) Following Insight Conference
September 28, 2016 8:51 AM EDTSusquehanna reiterated a Positive rating and $42.00 price target on NetApp (NASDAQ: NTAP) following the company's annual Insight conference in Las Vegas.
Analyst Mehdi Hosseini commented, "We came away from NTAP's Insight technical conference with increased comfort in our aboveconsensus view on FY18 revenue... More
Jefferies Remains Sidelined on NetApp (NTAP) Following Analyst Meeting
September 28, 2016 7:50 AM EDTJefferies reiterated a Hold rating on NetApp (NASDAQ: NTAP), and raised the price target to $34.00 (from $29.00), following an analyst meeting. NetApp noted it had reach #2 in market share in the AllFlash Array market. Like last year, CEO George Kurian gave a impassioned... More
Needham & Company Reiterates Hold on NetApp (NTAP) Following Analyst Day and User Conference
September 28, 2016 7:12 AM EDTNeedham & Company reiterated a Hold rating on NetApp (NASDAQ: NTAP) following the company's annual Insight user conference and Analyst day. No new financial information was presented. However, the company refreshed its FAS lines to incorporate both faster networking speeds and became... More
NetApp (NTAP): Raising PT After Insight 2016 Conference - Baird
September 28, 2016 6:33 AM EDTBaird analyst, Jayson Noland, reiterated his Outperform rating on shares of NetApp (NASDAQ: NTAP) after the company's Insight 2016 conference.
CEO Kurian gave a keynote address Monday evening emphasizing the shift from HDD to Flash and silos to scale-out. The company cited its recent move to No.2 in the All-Flash Array market and said firmly that it intends to be No.1 which would require substantial market share gain relative to... More
RBC Capital Raises Price Target on NetApp (NTAP) to $36
September 27, 2016 7:37 AM EDTRBC Capital reiterated a Sector Perform rating on NetApp (NASDAQ: NTAP), and raised the price target to $36.00 (from $32.00), following the Insight 2016 General Session. The highlights included presentations from management and partners.
Analyst Amit Daryanani commented, "1) Digital Transformation: Enterprises increasingly view digital transformation as... More
Notable Analyst Rating Changes 9/26: (DBD) (ETE) (ANDE) Upgraded; (DRH) (NTAP) (LYG) Downgraded
September 26, 2016 10:24 AM EDTUPGRADES
JPMorgan upgrades Diebold (NYSE: DBD) from Neutral to Overweight with a price target of $33.... More
Pre-Open Stock Movers 09/26: (ARRY) (CHMT) (GWPH) Higher; (PTIE) (DRRX) (SALE) Lower (more...)
September 26, 2016 9:29 AM EDTPain Therapeutics, Inc. (Nasdaq: PTIE) 64.5% LOWER; announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) on the resubmission of its new drug application (NDA) for REMOXY ER (oxycodone capsules CII). The CRL informs that REMOXY ER cannot be approved in its present form and specifies additional actions and data that are needed for drug approval.
Array BioPharma (Nasdaq: ARRY) 28% HIGHER; Array and Pierre Fabre jointly announced top-line... More
Deutsche Bank Downgrades NetApp (NTAP) to Sell
September 26, 2016 7:41 AM EDTDeutsche Bank downgraded NetApp (NASDAQ: NTAP) from Hold to Sell with a price target of $25. Analyst Sherri Scribner said secular storage market challenges aren't reflected in valuation.
"We are downgrading NTAP to a Sell from a Hold. NTAP shares are up... More

